We're dedicated to improve womens health through science.
Science
Oncology
- High-grade serous epithelial ovarian cancer (HGSOC) is the leading cause of death from gynecologic malignancies and the fifth most common cause of cancer-related death among women in the United States. With one in three women affected by poor ovarian health, there is a significant unmet need for effective treatments.
- Akkadian Therapeutics is addressing this challenge with our lead p53 mutant reactivator, AKT100. This compound has demonstrated robust activity both as a single agent and in combination with PARP inhibitors across multiple preclinical assays. AKT100 is currently in the early drug discovery stage.
Preeclampsia (PE)
- Preeclampsia is a serious complication affecting 5-7% of pregnancies globally. It is characterized by high maternal blood pressure, kidney dysfunction, and proteinuria, and can lead to eclampsia in severe cases. Currently, there are no therapies available to treat the underlying causes of preeclampsia. The most effective course of action is often premature delivery, which carries risks of reduced newborn survival and long-term developmental impairment.
- Akkadian Therapeutics is developing AKT1005 as a potential therapy for preeclampsia. In both in vitro studies and an established rodent model, AKT1005 has demonstrated significant benefits, including the reversal of maternal hypertension, a reduction in oxidative stress markers, and the prevention of kidney dysfunction. AKT1005 is currently in the early preclinical stage of development.
Postural Orthostatic Tachycardia Syndrome (POTS)
- Postural Orthostatic Tachycardia Syndrome (POTS) affects millions of people globally, primarily young women between the ages of 15 and 25. As a chronic disorder of the autonomic nervous system, it causes dizziness and an elevated heart rate when transitioning from sitting to standing by impacting the body's regulation of blood pressure and respiration.
- Akkadian is dedicated to staying at the forefront of research and technology to improve women's health in this evolving industry. We are currently developing AKT2000 series compound as a potential therapy for POTS.
Pipeline
Publications
- Williams GL. et al. The novel curcumin analogue AKT-100 targets mutant p53 in gynecologic cancer cells. bioRxiv [Preprint]. 2025 Oct 9:2025.10.06.680794. doi: 10.1101/2025.10.06.680794. PMID: 41279406; PMCID: PMC12632496.
- Ray KP. et al. Pharmacological advances in cannabinoid-based therapies for pancreatic cancer: preclinical efficacy of CCL-106 and its epimers. ESMO Gastrointest Oncol. 2025 Sep;9 PubMed Central PMCID: PMC12478540.
- Pintye D et al. A Novel Dual-Function Redox Modulator Relieves Oxidative Stress and Anti-Angiogenic Response in Placental Villus Explant Exposed to Hypoxia-Relevance for Preeclampsia Therapy. Biology (Basel). 2023 Sep 12;12(9) PubMed Central PMCID: PMC10525611.
- Pintye D. et al. A Novel Dual-Function Nitric Oxide Donor Therapy for Preeclampsia-A Proof-of-Principle Study in a Murine Model. Antioxidants (Basel). 2023 Nov 23;12(12) PubMed Central PMCID: PMC10741224.
Our Team and Research Collaborators
- Our founders are accomplished scientists who have developed a range of oncology, CNS, and ocular drugs. The team includes internationally recognized experts in critical illness, including one founder who has authored 175 peer-reviewed publications on free radical stress, reperfusion injury, and circulatory shock. Additionally, our leadership includes former pharmaceutical executives and directors with 30 years of experience overseeing drug discovery and development, medicinal chemistry, basic research, pharmacology, quality assurance, regulatory affairs, GMP manufacturing, and clinical investigation.
- Akkadian's research collaborators and consultants are renowned international scholars and seasoned professionals from the University of New Mexico, Albuquerque, NM; Beth Israel Deaconess Medical Center, Boston, MA and Karmanos Cancer Institute, Detroit, MI.
- Our team’s diverse expertise includes clinician-scientists, oncologists, medicinal chemists, pharmacologists, toxicologists, metabolism specialists, pathologists, statisticians, and molecular and cell biologists. Collectively, we have authored hundreds of publications in top-tier journals, including Nature, Nature Medicine, Nature Biology, Cancer Research, Endocrinology, Journal of the American Society of Nephrology, J Exp Med, J Med Chem, Biology, Circulation, Gastroenterology, J Clinical Investigation, and PNAS.